OPTX

Business Context and Reporting Period

Company: Syntec Optics Holdings, Inc. (OPTX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Syntec Optics is a vertically integrated manufacturer of optics and photonics components and sub-systems serving defense, medical, consumer, and communications end-markets. The company operates as a single reporting segment from its facility in Rochester, New York.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 26% year-over-year for the quarter ($8.3M vs. $6.6M) and 9% for the six-month period ($14.8M vs. $13.6M). Growth was driven by increases in defense, consumer, and communications sectors, partially offset by a temporary decline in medical sales due to a prior quarter shipping hold.
• Profitability Turnaround: The company reported a net income of $256,237 for the quarter, reversing a net loss of $343,921 in the same period in 2025. However, the six-month period remained in a net loss of $641,620 due to a significant loss in Q1 2026.
• Liquidity Transformation: Cash balances surged from $358,867 at year-end 2025 to $14.0 million at June 30, 2026. This was primarily driven by a public offering of common stock in April/May 2026, which generated approximately $21.4 million in net proceeds.
• Debt Reduction: The company utilized proceeds from the equity offering to fully repay its $6.8 million line of credit with M&T Bank and voluntarily cancelled the facility in June 2026, eliminating associated covenants and usage fees.
• Margin Pressure: While Q2 gross margin improved to 26%, the six-month gross margin declined to 21% (from 29% in 2025) due to increased material costs, specifically aluminum, and lower Q1 performance.

Guidance, Outlook, and Risks

• Capital Allocation: Management expects cash from operations and the recent equity offering to fund operations and working capital for at least the next 12 months. Proceeds were used to pay down debt and support growth initiatives.
• Market Expansion: The company is expanding into AI-driven military augmented reality (AR) wearables, biomedical mirrors, and low earth satellite optics. It is also engaged in a NIST-funded R&D project for the sensing end-market.
• Index Inclusion: In Q2 2026, the company's stock was added to the Russell 3000 Index, expected to enhance visibility and liquidity.
• Material Weaknesses in Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026. Identified material weaknesses include:
  • Lack of formal documentation for internal control processes and segregation of duties.
  • Lack of timely reconciliation controls for accounts payable and taxes.
  • Insufficient controls for identifying related party transactions and evaluating non-routine transactions.
  • Inadequate IT general controls regarding user access and cybersecurity.
• Customer Concentration: Three customers accounted for 52% of revenues for the three and six months ended June 30, 2026.

Investor Verification Checklist

• Equity Offering Details: Verify the final net proceeds and share count from the April/May 2026 underwritten public offering and the exercise of the underwriter's option.
• Debt Covenant Status: Confirm the formal cancellation of the M&T Bank line of credit and the removal of Fixed Charge Coverage and Total Leverage Ratio covenants.
• Internal Control Remediation: Review the specific timeline and progress of the remediation plan for the five identified material weaknesses in internal controls over financial reporting.
• Medical Sector Recovery: Monitor the status of the previously held medical customer shipments to ensure Q3 revenue reflects a full recovery.
• Subsequent Events: Note the July 2026 filing of an S-1 registration statement for the resale of up to 30.7 million shares by selling stockholders (no proceeds to the company).